News | August 05, 2025
Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
India’s nutraceutical industry is expected to reach over US$ 22 billion in 2025
The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
Scores highest PAT of Rs. 118 crore in FY25
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
Tatva Chintan Pharma Chem receives export order worth $35, 55,000
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
